Spero Therapeutics (NASDAQ:SPRO) Announces Earnings Results

Spero Therapeutics (NASDAQ:SPRO) posted its earnings results on Wednesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, FiscalAI reports. The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $43.34 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%.

Spero Therapeutics Price Performance

Spero Therapeutics stock traded down $0.10 during mid-day trading on Wednesday, hitting $2.44. 673,527 shares of the company were exchanged, compared to its average volume of 438,896. Spero Therapeutics has a 12-month low of $0.63 and a 12-month high of $3.22. The company has a market capitalization of $141.28 million, a P/E ratio of 20.34 and a beta of 1.43. The business’s 50 day simple moving average is $2.54 and its two-hundred day simple moving average is $2.42.

Insider Activity

In related news, insider Esther Rajavelu sold 25,240 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $2.51, for a total transaction of $63,352.40. Following the sale, the insider owned 986,851 shares of the company’s stock, valued at $2,476,996.01. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SPRO. Quadrature Capital Ltd purchased a new position in Spero Therapeutics in the 4th quarter valued at about $88,000. Millennium Management LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter worth about $56,000. Squarepoint Ops LLC acquired a new position in shares of Spero Therapeutics in the fourth quarter valued at approximately $278,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Spero Therapeutics during the fourth quarter valued at approximately $306,000. Finally, State Street Corp lifted its stake in shares of Spero Therapeutics by 10.1% during the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after buying an additional 19,200 shares during the period. Institutional investors and hedge funds own 25.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wall Street Zen raised Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.